Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.2.1.52: beta-N-acetylhexosaminidase

This is an abbreviated version!
For detailed information about beta-N-acetylhexosaminidase, go to the full flat file.

Word Map on EC 3.2.1.52

Reaction

(N-acetyl-D-glucosamine)4
+ 3 H2O = 4 2-(acetylamino)-2-deoxy-beta-D-glucopyranose

Synonyms

2-acetamido-2-deoxy-beta-D-glucoside acetamidodeoxyglucohydrolase, 3-beta-N-acetylglucosaminidase, 65 kDa epididymal boar protein, Am2301, Am2446, At1g65600/F5I14_13, beta-acetylaminodeoxyhexosidase, beta-acetylhexosaminidase, beta-acetylhexosaminidinase, beta-D-hexosaminidase, beta-D-N-acetylhexosaminidase, Beta-GlcNAcase, beta-glucosidase, beta-HEX, beta-HexNAcase, beta-hexosaminidase, beta-hexosaminidase A, beta-hexosaminidase B, beta-hexosaminidase I, beta-hexosaminidase II, beta-N-acetyl-D-glucosaminidase, beta-N-acetyl-D-hexosaminidase, beta-N-acetyl-hexosaminidase, beta-N-acetylgalactosaminidase, beta-N-acetylglucosaminidase, Beta-N-acetylhexosaminidase, beta-N-acetylhexosaminidase A, beta-N-acetylhexosaminidase B, beta-Nacetylhexosaminidase S, beta-NAGase, beta-NAHA, Beta-NAHASE, bifunctional exo-beta-glucosidase/N-acetyl-beta-glucosaminidase, BmCHI-h, BmGlcNAcase 1, BmGlcNAcase 2, BmNPV CHIA, CbsA, Chi-I, Chi-II, chitobiase, chitobiase 2, CpGV V-CHIA, dispersin B, DmHEXA, DmHEXB, DspB, EC 3.2.1.29, EC 3.2.1.30, endo-beta-N-acetylglucosaminidase, EXC1Y, EXC2Y, exo-acting chitinase, exo-beta-D-N-acetylglucosaminidase, exo-beta-hexosaminidase, exo-type beta-N-acetylhexosaminidase, exochitinase, F3F20.4 protein, FDL, GH84C, GlcNAcase, Hex, Hex A, Hex B, Hex-1, Hex1, Hex2, Hex20, Hex4, HexB, HexD, HEXDC, hEXO1, HEXO2, HEXO3, hexosaminidase, hexosaminidase A, hexosaminidase B, hexosaminidase D, hHexA, lacto-N-biosidase, lnba, lysosomal beta-hexosaminidase, More, N-acetyl-beta-D-hexosaminidase, N-acetyl-beta-glucosaminidase, N-acetyl-beta-hexosaminidase, N-acetylglucosaminidase, N-acetylhexosaminidase, NAG-68, NAG-B, NAG1, NAG2, Nag3, NagA, NAGase, NagJ, NagZ, NAHA, NAHase, neutral hexosaminidase C, O-GlcNAcase, Pcb-NAHA1, Sfhex, SSO3039, StrH, zymocin alpha-subunit

ECTree

     3 Hydrolases
         3.2 Glycosylases
             3.2.1 Glycosidases, i.e. enzymes that hydrolyse O- and S-glycosyl compounds
                3.2.1.52 beta-N-acetylhexosaminidase

Inhibitors

Inhibitors on EC 3.2.1.52 - beta-N-acetylhexosaminidase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1E)-2-nitro-1H-indene-1,3(2H)-dione oxime
-
-
(1Z)-2-nitro-1H-indene-1,3(2H)-dione oxime
-
-
(2E)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-(2-thienylcarbonyl)acrylonitrile
-
-
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2Z)-2-[(2E)-[(naphthalen-1-yl)methylidene]hydrazinylidene]-3-(2-phenoxyethyl)-1,3-thiazolidin-4-one
-
56.4% inhibition at 0.1 mM
(3aR,5R,6R,7R,7aR)-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol
-
-
(3aR,5R,6S,7R,7aR)-3a-(aminomethyl)-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol
-
-
(3aR,5R,6S,7R,7aR)-5-(hydroxymethyl)-2,3a-dimethyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol
-
-
(3aR,5R,6S,7R,7aR)-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol
-
-
(3E)-1-methyl-3-([[3-(trifluoromethyl)phenyl]amino]methylene)-1H-thieno[3,2-c][1,2]thiazin-4(3H)-one 2,2-dioxide
-
-
(3R,4R,5R,6S),N-(4,5,6-trihydroxyazepan-3-yl)-acetamide
-
68% inhibition at 1 mM
(3R,4R,5R,6S)-N-(4,5,6-trihydroxy-azepan-3-yl)-acetamide
-
93% inhibition at 1 mM
(3R,4S,5R,6R,7R),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
(3S,4R,5R,6R,7R),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
(3S,4R,5R,6R,7R),N-(4,5,6-trihydroxy-7-hydroxymethyl-azepan-3-yl)-acetamide
(3S,4R,5R,6R,7S),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
(3S,4R,5R,6S),N-(4,5,6-trihydroxyazepan-3-yl)-acetamide
-
99% inhibition at 1 mM
(5R,6R,7R)-5-(hydroxymethyl)-2-methyl-6,7-dihydro-5H-pyrano[3,2-d][1,3]thiazole-6,7-diol
-
-
(N-acetyl-D-glucosamine)2
non-competitive
(N-acetyl-D-glucosamine)3-6
competitive inhibition
(Z)-2-(((E)-benzylidene)hydrazono)-3-((benzyloxy)methyl)thiazolidin-4-one
-
62.7% inhibition at 0.01 mM; 62.7% inhibition at 0.1 mM
(Z)-2-(((E)-benzylidene)hydrazono)-3-(2-phenoxyethyl)thiazolidin-4-one
-
79.4% inhibition at 0.01 mM
(Z)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)-3-(2-phenoxyethyl) thiazolidin-4-one
-
56.4% inhibition at 0.01 mM
(Z)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)-3-(2-phenoxyethyl)thiazolidin-4-one
-
35.5% inhibition at 0.01 mM
(Z)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)-3-(prop-2-yn-1-yl) thiazolidin-4-one
-
8.8% inhibition at 0.1 mM
(Z)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)-3-(prop-2-yn-1-yl)thiazolidin-4-one
-
8.8% inhibition at 0.1 mM
(Z)-3-((2-chlorothiazol-5-yl)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono) thiazolidin-4-one
-
39% inhibition at 0.1 mM
(Z)-3-((2-chlorothiazol-5-yl)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)thiazolidin-4-one
-
39% inhibition at 0.1 mM
(Z)-3-((3,5-dimethylisoxazol-4-yl)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono) thiazolidin-4-one
-
34.5% inhibition at 0.1 mM
(Z)-3-((3,5-dimethylisoxazol-4-yl)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)thiazolidin-4-one
-
34.5% inhibition at 0.1 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-(4-bromo naphthalen-1-yl)methylene)hydrazono) thiazolidin-4-one
-
43.7% inhibition at 0.01 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-(4-bromonaphthalen-1-yl)methylene)hydrazono)thiazolidin-4-one
-
43.7% inhibition at 0.1 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-4-(dimethylamino)benzylidene)hydrazono)thiazolidin-4-one
-
63.5% inhibition at 0.01 mM; 63.5% inhibition at 0.1 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono) thiazolidin-4-one
-
85.9% inhibition at 0.1 mM, 35.5% inhibition at 0.01 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)thiazolidin-4-one
-
85.9% inhibition at 0.1 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-naphthalen-2-ylmethylene)hydrazono)thiazolidin-4-one
-
59.8% inhibition at 0.01 mM; 59.8% inhibition at 0.1 mM
(Z)-3-(4-chlorobenzyl)-2-(((E)-naphthalen-1-yl methylene)hydrazono)thiazolidin-4-one
-
53.2% inhibition at 0.1 mM
(Z)-3-(4-fluorobenzyl)-2-(((E)-naphthalen-1-yl methylene)hydrazono)thiazolidin-4-one
-
41.7% inhibition at 0.1 mM
(Z)-3-(cyclobutylmethyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)thiazolidin-4-one
-
9.0% inhibition at 0.1 mM
(Z)-3-(cyclopropylmethyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)thiazolidin-4-one
-
1.0% inhibition at 0.1 mM
(Z)-3-allyl-2-(((E)-naphthalen-1-ylmethylene) hydrazono)thiazolidin-4-one
-
21.9% inhibition at 0.1 mM
(Z)-3-ethyl-2-(((E)-naphthalen-1-ylmethylene) hydrazono)thiazolidin-4-one
-
28.1% inhibition at 0.1 mM
1,1'-(1,3-dioxo-2-phenylpropane-1,3-diyl)bis(2,3-dihydro-1H-indole)
-
-
1,10-phenanthroline
-
concentration of 1 mM causes 25% inhibition
1,2,3-tris-[1-(2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1->4)-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)-2-ethyloxy]benzene
-
1,2-dideoxy-2'-butyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,2-dideoxy-2'-ethyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,2-dideoxy-2'-isobutyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,2-dideoxy-2'-isopropyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,2-dideoxy-2'-methyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
an inhibitor that mimics the oxazoline intermediate proposed in the catalytic mechanism of family 20 glycoside hydrolases, is shown to act as a potent competitive inhibitor. About 17000fold more tightly than GlcNAc
1,2-dideoxy-2'-pentyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,2-dideoxy-2'-propyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,3,4,6-tetra-O-acetyl-2-deoxy-2-[3-(1-adamantyl)ureido]-beta-D-glucopyranose
-
0.1 mM
1,3,4,6-tetra-O-acetyl-2-deoxy-2-[3-(2-allyl)thioureido]-beta-D-glucopyranose
-
0.1 mM
1,3,4,6-tetra-O-acetyl-2-deoxy-2-[3-(2-cyclohexyl)ureido]-beta-D-glucopyranose
-
0.1 mM
1,3-bis[3-(1-deoxy-D-glucit-1-yl)ureido]-4-methylbenzene
-
0.1 mM
1,6-bis[3-(1,3,4,6-tetra-O-acetyl-2-deoxy-beta-D-glucopyranos-2-yl)ureido]hexane
-
0.1 mM
1,6-bis{1-[3-(1-deoxy-D-glucit-1-yl)]ureido}hexane
-
0.1 mM
1,8-bis[3-(1,3,4,6-tetra-O-acetyl-2-deoxy-beta-D-glucopyranos-2-yl)ureido]octane
-
0.1 mM
1,9-bis-[3-(2-hydroxyethoxy)ethylthioureido]-nonane
-
0.1 mM
1,9-bis{1-[3-(1-deoxy-D-glucit-1-yl)]thioureido}nonane
-
0.1 mM
1-acetamido-2-deoxy-D-glucono-1,5-lactone
-
-
1-deoxy-1-(3-adamantylthioureido)-D-glucitol
-
0.1 mM
1-deoxy-1-(3-cyclohexylureido)-D-glucitol
-
0.1 mM
1-deoxy-1-[3-(1-adamantyl)ureido]-D-glucitol
-
0.1 mM
1-[2-(1H-benzimidazol-2-yl)phenyl]-3-[4-(benzyloxy)phenyl]urea
-
-
1-[5-acetyl-2-[4-(ethoxycarbonyl)piperidin-1-yl]phenyl]-1-methyldiazenium
-
-
2,2''-[azanediyldi(ethane-2,1-diyl)]di(1H-benzo[de]isoquinoline-1,3(2H)-dione)
-
M-31850
2,2'-(iminodiethane-2,1-diyl)bis(1H-benzo[de]isoquinoline-1,3(2H)-dione)
-
-
2-(2-([(4-methoxyphenyl)methyl]amino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-(2-([(5-methyl-1,3,4-thiadiazol-2-yl)methyl]amino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-(2-hydroxypropyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-(2-pyridin-2-ylethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-(4-chlorobenzyl)-5-methyl-2,6-dihydro-1H-pyrrolo[3,4-d]pyridazin-1-one
-
-
2-(tetrahydrofuran-2-ylmethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-acetamido-1,2,4-trideoxy-1,4-imino-D-arabinitol
2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
2-acetamido-1,2,5-trideoxy-1,5-imino-D-glucitol
-
-
2-acetamido-1,2-deoxynojirimycin
-
2-acetamido-1,2-dideoxy-1,5-imino-D-glucitol
-
competitive inhibitor
2-acetamido-1,2-dideoxynojirimycin
2-acetamido-2-deoxy-D-fucono(1-4)lactone
-
-
2-acetamido-2-deoxy-D-galactono(1-4)lactone
2-acetamido-2-deoxy-D-galactonolactone
-
-
2-acetamido-2-deoxy-D-galactose
-
-
2-acetamido-2-deoxy-D-glucose
-
-
2-acetamido-2-deoxy-D-mannono-1,4-lactone
-
-
2-acetamido-2-deoxy-L-arabinono(1-4)lactone
-
-
2-acetamido-2-deoxy-N-([4-[(2,4-dichlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(2,6-dichlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(2-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(2-hydroxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(2-methoxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-alpha-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(2-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(3-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(3-hydroxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(3-methoxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(3-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(4-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(4-methoxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
6.9% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(4-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-[(4-[[2-(trifluoromethyl)benzamido]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-beta-D-glucopyranosylamine
2-acetamido-2-deoxyglucono-1,4-lactone
2-acetamido-6-azido-2,6-dideoxy-D-galactono(1-4)lactone
-
-
2-acetamido-N-([4-[(2-amino-3-methylbenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-([4-[(2-aminobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
-
5.1% inhibition at 0.1 mM
2-acetamido-N-([4-[(2-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-([4-[(3-aminobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-([4-[(3-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-([4-[(4-aminobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
-
13.5% inhibition at 0.1 mM
2-acetamido-N-([4-[(4-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-[(4-[[([1,1'-biphenyl]-2-carbonyl)amino]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
-
28.5% inhibition at 0.1 mM
2-acetamido-N-[(4-[[([1,1'-biphenyl]-3-carbonyl)amino]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-[(4-[[([1,1'-biphenyl]-4-carbonyl)amino]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-[(4-[[4-chloro-2-(propan-2-yl)benzamido]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
2-amino-1H-benzo[de]isoquinoline-1,3(2H)-dione
28.1% inhibition at 0.1 mM
2-amino-4-ethyl-5-(4-(trifluoromethyl)phenyl)pyrimidine
-
-
2-amino-4-ethyl-5-(4-chlorophenyl)pyrimidine
-
-
2-amino-6-(methoxymethyl)pyrimidin-4-ol
-
-
2-amino-6-ethyl-5-(4-chlorophenyl)pyrimidin-4(3H)-one
-
-
2-deoxy-2-(trimethylammonio)-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-D-glucopyranose
2-deoxy-2-acetamido-D-glucono(1-5)lactone
2-hydroxy-3-phenyl-4H-pyrimido[2,1-b][1,3]benzothiazol-4-one
-
-
2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-D-glucopyranose
2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-D-glucopyranose
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-(81-[5-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)pentyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-([1-[3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-([1-[4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
2-[2-[(2-acetamido-beta-D-glucopyranosyl)thio]ethyl]-1H-benzo[de]isoquinoline-isoquinoline-1,3(2H)-dione
-
-
2-[2-[2-[(2-acetamido-beta-D-glucopyranosyl)thio]ethylamino]ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[2-[3-[(2-acetamido-beta-D-glucopyranosyl)thio]propylamino]ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[2-[5-[(2-acetamido-beta-D-glucopyranosyl)thio]pentylamino]ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[2-[6-[(2-acetamido-beta-D-glucopyranosyl)thio]hexylamino]ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[3-[(2-acetamido-beta-D-glucopyranosyl)thio]propyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[3-[2-[(2-acetamido-beta-D-glucopyranosyl)thio]ethylamino]propyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[3-[3-[(2-acetamido-beta-D-glucopyranosyl)thio]propylamino]propyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[3-[5-[(2-acetamido-beta-D-glucopyranosyl)thio]pentylamino]propyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[3-[6-[(2-acetamido-beta-D-glucopyranosyl)thio]hexylamino]propyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[4-[(2-acetamido-beta-D-glucopyranosyl)thio]butyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[4-[2-[(2-acetamido-beta-D-glucopyranosyl)thio]ethylamino]butyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[4-[3-[(2-acetamido-beta-D-glucopyranosyl)thio]propylamino]butyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[4-[5-[(2-acetamido-beta-D-glucopyranosyl)thio]pentylamino]butyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[4-[6-[(2-acetamido-beta-D-glucopyranosyl)thio]hexylamino]butyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[5-[(2-acetamido-beta-D-glucopyranosyl)thio]pentyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[6-[(2-acetamido-beta-D-glucopyranosyl)thio]hexyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[[1-[(2-acetamido-beta-D-glucopyranosylthiomethyl)-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
17.9% inhibition at 0.1 mM
2-[[1-[2-[(2-acetamido-beta-D-glucopyranosyl)thio]ethyl]-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
84% inhibition at 0.1 mM
2-[[1-[3-[(2-acetamido-beta-D-glucopyranosyl)thio]propyl]-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
81.6% inhibition at 0.1 mM
2-[[1-[4-[(2-acetamido-beta-D-glucopyranosyl)thio]butyl]-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
89.9% inhibition at 0.1 mM
2-[[1-[5-[(2-acetamido-beta-D-glucopyranosyl)thio]pentyl]-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
91.9% inhibition at 0.1 mM
2-[[1-[6-[(2-acetamido-beta-D-glucopyranosyl)thio]hexyl]-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
93.2% inhibition at 0.1 mM
3,5-bis(4-fluorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
-
3-methoxy-1-(3,4,5-trimethoxyphenyl)-9,10-dihydrophenanthrene-2-carbonitrile
-
-
3-[2-(benzyloxy)-5-fluorophenyl]-5-(4-tert-butylphenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole
-
-
4,5-dihydronaphtho[1,2-b]thiophene-2-carbohydrazide
-
-
4-ethyl-5-[4-(trifluoromethyl)phenyl]pyrimidine
-
-
4-hydroxy-3-(methylthio)-N'-[(1E)-2-thienylmethylene]-4,5,6,7-tetrahydro-2-benzothiophene-1-carbohydrazide
-
-
4-nitrophenyl 2-acetamido-2-deoxy-beta-D-galactopyranoside
-
substrate inhibition, competitive
4-nitrophenyl 2-acetamido-2-deoxy-beta-D-glucopyranoside
-
substrate inhibition, noncompetitive
4-[(E)-2-phenylvinyl]benzaldehyde O-(anilinocarbonyl)oxime
-
-
4-[4-(phenylethynyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]butanamide
-
-
5-(3,5-dimethylphenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(3-nitrophenyl)-2-furaldehyde N-(3-fluorophenyl)thiosemicarbazone
-
-
5-(4-chloro-1-methyl-1H-pyrazol-3-yl)-4,5-dihydro-1,3,4-thiadiazole-2-thiol
-
-
5-(4-chlorophenyl)-6-butylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-isopropylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-methylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-propylpyrimidine-2,4-diamine
-
-
6-(aminomethyl)-5-(4-chlorophenyl)pyrimidine-2,4-diamine
-
-
6-(dimethylamino)-2-(2-([(5-methyl-1,3,4-thiadiazol-2-yl)methyl]amino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
95.9% inhibition at 0.1 mM
6-ethyl-5-(4-(trifluoromethyl)phenyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-(4-methoxyphenyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-(m-tolyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-(o-tolyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-(p-tolyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-phenylpyrimidine-2,4-diamine
-
-
7-diazonaphthalene-1,3-disulfonic acid
-
extract: 45% of activity remains
acetamide
acetate
AgNO3
AlCl3
allyl ((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyrano-syl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)carbamate
antibodies
-
inhibit about 90% of in vitro activity
-
ascorbate
-
only in presence of Cu2+
beta-D-GalNAc-(1->4)beta-D-GlcNAc
-
beta-mercaptoethanol
-
with 2 mM hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside is reduced to 22%, hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside to 20%
CaCl2
chitobiose
-
concentration of 10 mM causes 25% inhibition
Chloramine T
-
0.1 mM, complete inhibition
CoCl2
conduritol beta-epoxide
-
CuCl2
-
5 mM, 37% inhibition
CuSO4
D-fructose
-
3 mM, 26% inhibition
D-mannose
diethyl dicarbonate
-
with 30 mM 1.1% of activity remains
dioxane
-
reversible inactivation, mixed-type inhibition, half-maximal inhibition at 0.68%
dithioerythritol
-
concentration of 2.5 mM decreases activity of the 3 enzyme forms in colonic mucosa by 20% at pH 4.2 and by 25% at pH 7.0, similar results with the 2 forms from colon tumors
dsRNA
mediates transcript depletion. Knockdown of transcripts results in phenotypes similar to those of NAG1 dsRNA-treated insects, but the effects are somewhat variable and less severe; mediates transcript depletion. Knockdown of transcripts results in phenotypes similar to those of NAG1 dsRNA-treated insects, but the effects are somewhat variable and less severe; mediates transcript depletion. Knockdown of transcripts results in phenotypes similar to those of NAG1 dsRNA-treated insects, but the effects are somewhat variable and less severe; mediates transcript depletion, NAG1 dsRNA is most effective in interrupting all three types of molts: larval-larval, larval-pupal, and pupal-adult, treated insects die after failing to completely shed their old cuticles
-
E-64
about 70% residual activity at 1 mM
elinafide
-
-
erythritol
-
64.4% relative inhibition, three concentrations of 10, 50, and 100 mM tested
ethyl 3-(N-[[(4-chlorophenyl)amino]carbonyl]-S-methylsulfinimidoyl)-6,7-dihydro-2-benzothiophene-1-carboxylate
-
-
ethyl 5-[[3-(trifluoromethyl)phenyl]amino]pyrazolo[1,5-a]quinazoline-3-carboxylate
-
-
FeCl3
fructose
-
concentration of 10 mM causes 38% inhibition
fucoidan
Gal-NAG-thiazoline
-
-
galactonolactone
-
-
galactosamine
galactose
GalNAc-isofagomine
-
GlcNAc
gluconolactone
-
-
glucosamine
Glucosamine-HCl
-
-
glucose
HgCl2
high ionic strength
-
above 0.1 no cleavage of GM2
-
iminocyclitol
-
-
iodoacetamide
K+
-
slight inhibition at 5 mM
KCl
with 1 mM 80% of activity remains, with 2 mM 50% of activity remains
lactose
leupeptin
about 90% residual activity at 1 mM
LOGNAc
i.e. 2-acetamido-2-deoxy-D-gluconhydroximo-1,5-lactone
maltose
mannosamine
methyl-alpha-D-mannoside
-
concentration of 10 mM causes 25% inhibition
MgCl2
-
1 mM, 13% inhibition
MgSO4
-
10 mM, 22% inhibition
MnCl2
-
1 mM, complete inhibition
Monoiodoacetic acid
-
with 1 mM 73% of activity remains
N,N,N,N-tetraacetylchitotetraose
N,N,N-triacetylchitotriose
N,N-diacetylchitobiose
N-((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyranosyl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide
N-((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyranosyl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)picolinamide
N-((3S,4R,5S)-1-(7-(bis(4-methoxybenzyl)amino)heptyl)-4,5-dihydroxy-5-(hydroxymethyl)piperidin-3-yl)acetamide
-
-
N-((3S,4R,5S)-4,5-dihydroxy-5-(hydroxymethyl)-1-(7-(4-methoxybenzylamino)heptyl)piperidin-3-yl)acetamide
-
-
N-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-2-[(2-acetamido-beta-D-glucopyranosyl)thio]acetamide
24.9% inhibition at 0.1 mM
N-(3,5-dichlorophenyl)-2-[[4-(3,4-dimethylthieno[2,3-b]thien-2-yl)pyrimidin-2-yl]thio]acetamide
-
-
N-(3R,4S,5R,6R,7S)-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
N-(7-((3S,4R,5S)-5-acetamido-3,4-dihydroxy-3-(hydroxymethyl)piperidin-1-yl)heptyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide
-
-
N-acetyl-beta-D-galactosamine
N-acetyl-beta-D-galactosaminolactone
N-acetyl-beta-D-glucosamine
N-acetyl-beta-D-glucosaminolactone
N-acetyl-D-galactosamine
N-acetyl-D-glucosamine
N-acetylcastanospermine
30% with 1 mM inhibitor and 2.5 mM substrate
N-acetylgalactosamine
-
61.9% relative inhibition, three concentrations of 10, 50, and 100 mM tested
N-acetylglucosamine
-
76.2% relative inhibition, three concentrations of 10, 50, and 100 mM tested
N-acetylglucosamine thiazoline
-
-
N-acetylglucosamine(1-5)lactone
-
-
N-acetylglucosamine-6-sulfate
-
with 10 mM 86% of activity remains
N-acetylglucosamine-isothiocyanate
-
with 10 mM 46% of activity remains
N-Acetylimidazole
-
1 mM, 31% inhibition
N-acetylleucine
-
-
N-acetylmannosamine
N-benzyl-2-acetamido-1,2,4-trideoxy-1,4-imino-D-arabinitol
N-benzyl-2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
N-bromosuccinimide
N-butyl-2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
-
-
N-butyldeoxynojirimycin
-
N-ethyl-5-phenyl-isoxazolium-3'-sulfonate
-
with 30 mM 23.3% of activity remains
N-ethylmaleimide
N-[(1S,2R,5R,6R)-2-amino-5,6-dihydroxy-4-(hydroxymethyl)-cyclohex-3-en-1-yl]acetamide hydrochloride
N-[(3S,4R,5R,6S)-4,5,6-trihydroxyazepan-3-yl]acetamide
N-[1(7-amino-heptyl)]-2-acetamido-1,2,5-trideoxy-1,5-imino-D-glucitol
-
competitive inhibitor
N-[1(7-azido-heptyl)]-2-acetamido-1,2,5-trideoxy-1,5-imino-D-glucitol
-
-
N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl]-2-[(2-acetamido-beta-D-glucopyranosyl) thio]acetamide
18.4% inhibition at 0.1 mM
N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl]-2-[(2-acetamido-beta-D-glucopyranosyl)thio]acetamide
18.4% inhibition at 0.1 mM
N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl]-3-[(2-acetamido-beta-D-glucopyranosyl)thio]propanamide
25.8% inhibition at 0.1 mM
N-[3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl]-2-[(2-acetamido-beta-D-glucopyranosyl)thio]acetamide
29.2% inhibition at 0.1 mM
N-[3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl]-3-[(2-acetamido-beta-D-glucopyranosyl)thio]propanamide
25.3% inhibition at 0.1 mM
N-[4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl]-2-[(2-acetamido-beta-D-glucopyranosyl)thio]acetamide
29.1% inhibition at 0.1 mM
N-[4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl]-3-[(2-acetamido-beta-D-glucopyranosyl)thio]propanamide
26.9% inhibition at 0.1 mM
N-[[1-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]-2-(2-acetamido-beta-D-glucopyranosylthio)acetamide
Na+
-
slight inhibition at 5 mM
Na2S2O3
-
9% inhibition at 1 mM
NAG-thiazoline
nagstatin
-
-
NaOH
-
unbroken bacteria: total inhibition with 1 M, extract: with 1 M 9% of activity remains
naphthalene-1,4-diyl bis(trifluoroacetate)
-
-
naphthalimide
NH4+
-
20% inhibition with 2 M, 5% inhibition with 2 M
Ni2+
-
strong inhibition at 5 mM
O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino-N-phenylcarbamate
-
PUGNAc
O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenylcarbamate
O-(2-deoxy-2-butamido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-(2-deoxy-2-hexamido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-(2-deoxy-2-isobutamido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-(2-deoxy-2-isovaleramido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-(2-deoxy-2-propamido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-(2-deoxy-2-valeramido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1-4)-2-acetamido-3-O-(D-carboxyethyl)-2-deoxy-D-glucose
-
substrate inhibition above 0.2 mM
p-aminophenyl 1-thio-beta-L-fucopyranoside
-
-
p-chloromercuribenzoate
p-chloromercuriphenylsulfonate
p-hydroxymercuribenzoate
p-hydroxymercuribenzoic acid
-
1 mM, 22% inhibition
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
p-nitrophenyl 2-deoxy-2-thioacetamido-beta-D-galactopyranoside
-
competitive inhibition
p-nitrophenyl 2-deoxy-2-thioacetamido-beta-D-glucopyranoside
-
competitive inhibition
p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside
p-thiophenyl-1-thio-N-acetyl-beta-D-glucosaminide
-
-
Pb(NO3)2
-
10 mM, 50% inhibition
phenyl N-acetylgalactosaminide
-
-
phenyl N-acetylglucosaminide
-
-
Phenylglyoxal
-
1 mM, 20% inhibition
phenylmethanesulfonyl fluoride
about 35% residual activity at 1 mM
PUGNAc
pyrimethamine
RNAi
-
mediates mRNA suppression in S2 cells. About 50% reduction of Glc-NAcase activity through RNAi-mediated suppression regardless of applied dsRNA amounts compared to the case of original human erythropoietin-expressing S2 cells. GlcNAcase suppression decreases the amount of terminal Man available
-
S-(thiophen-3-ylmethyl) (2,2'-bithiophen-5-ylcarbonyl)thiocarbamate
-
-
SnCl2
-
10 mM, 44% inhibition
Sodium acetate
sodium taurodeoxycholate
-
-
sucrose
-
concentration of 10 mM causes 9% inhibition
tert-butyl {[(3aR,5R,6S,7R,7aR)-6,7-dihydroxy-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazol-3a-yl]methyl}carbamate
-
-
thimerosal
-
inhibits activity in mucosal and tumor enzymes, 50% of activity remains after 1 h if form A is treated with 0.20 mM, form B with 1.75 mM and form I with 0.65 mM
thioguanine
-
-
thiophenyl-N-acetyl-beta-D-glucosaminide
-
-
TMG-chitobiomycin
-
-
TMG-chitotriomycin
ZnSO4
-
1 mM, 77% inhibition
additional information
-